ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Published: 06 Mar 2023

  • Views:

    Views Icon 127
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US) and Dr Christopher B Granger (Duke University Medical Center, US) to discuss the results of the COORDINATE-Diabetes trial (NCT03936660).

The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). 
The trial involves cardiology clinics in the US and provides a multi-disciplinary approach to care, including education for clinicians and patients, patient tracking, and monthly clinician calls to review cases. The primary outcome is the proportion of patients receiving all three types of recommended medication (high-intensity statin, ACEi/ARB, and SGLT2i or GLP1RA) at the last follow-up visit.
The trial showed that a coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with T2DM and ASCVD.

For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.

Recorded remotely from Hamilton and Durham, 2023. 

Editor: Mirjam Boros

Video production: Oliver Miles & Dan Brent 


You must be to comment. If you are not registered, you can register here.